loading
전일 마감가:
$1.43
열려 있는:
$1.41
하루 거래량:
179.32K
Relative Volume:
0.08
시가총액:
$3.23M
수익:
-
순이익/손실:
$-6.91M
주가수익비율:
-0.4387
EPS:
-3.26
순현금흐름:
$-6.14M
1주 성능:
+2.88%
1개월 성능:
+4.38%
6개월 성능:
-50.00%
1년 성능:
-67.27%
1일 변동 폭
Value
$1.38
$1.46
1주일 범위
Value
$1.355
$1.5305
52주 변동 폭
Value
$1.15
$23.80

Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile

Name
명칭
Galmed Pharmaceuticals Ltd
Name
전화
-
Name
주소
-
Name
직원
6
Name
트위터
@GalmedPharma
Name
다음 수익 날짜
2025-03-26
Name
최신 SEC 제출 서류
Name
GLMD's Discussions on Twitter

GLMD을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
GLMD
Galmed Pharmaceuticals Ltd
1.43 3.14M 0 -6.91M -6.14M -3.26
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2020-05-22 다운그레이드 B. Riley FBR Buy → Neutral
2020-02-04 개시 Craig Hallum Buy
2020-01-30 재개 Cantor Fitzgerald Overweight
2019-12-02 개시 Canaccord Genuity Buy
2018-12-12 개시 B. Riley FBR Buy
2018-08-02 재확인 Maxim Group Buy
2018-07-13 개시 Stifel Buy
2018-07-12 개시 Cantor Fitzgerald Overweight
2018-06-12 재확인 H.C. Wainwright Buy
2018-03-15 업그레이드 Maxim Group Hold → Buy
2018-02-14 다운그레이드 Maxim Group Buy → Hold
2018-02-12 재확인 H.C. Wainwright Buy
2017-11-15 개시 ROTH Capital Buy
2017-08-08 재확인 H.C. Wainwright Buy
2017-07-31 재확인 Maxim Group Buy
2016-08-01 재확인 Maxim Group Buy
2016-07-06 재개 ROTH Capital Buy
2016-03-28 재개 H.C. Wainwright Buy
2015-06-23 개시 H.C. Wainwright Buy
2015-05-06 개시 Sun Trust Rbsn Humphrey Buy
모두보기

Galmed Pharmaceuticals Ltd 주식(GLMD)의 최신 뉴스

pulisher
May 27, 2025

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond Nash - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Galmed Pharmaceuticals Unveils Biomarker Signature for Aramchol, Expanding Market Potential - TipRanks

May 27, 2025
pulisher
May 27, 2025

Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH - WV News

May 27, 2025
pulisher
May 24, 2025

Wall Street Zen Upgrades Galmed Pharmaceuticals (NASDAQ:GLMD) to Sell - Defense World

May 24, 2025
pulisher
May 23, 2025

Galmed Pharmaceuticals: Q1 Earnings Snapshot - New Haven Register

May 23, 2025
pulisher
May 22, 2025

Galmed Pharmaceuticals Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Galmed Pharmaceuticals Reports Q1 2025 Financial Results and Advances in Oncology - TipRanks

May 22, 2025
pulisher
May 22, 2025

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire

May 22, 2025
pulisher
May 15, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Coverage Initiated at StockNews.com - Defense World

May 15, 2025
pulisher
May 14, 2025

Galmed Pharmaceuticals Unveils Promising Aramchol Results in PSC Models - TipRanks

May 14, 2025
pulisher
May 14, 2025

Galmed (GLMD) Announces Promising Pre-Clinical Results for Aramc - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Galmed (GLMD) Announces Promising Pre-Clinical Results for Aramchol in Treating PSC | GLMD Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models - PR Newswire

May 13, 2025
pulisher
May 10, 2025

Biotech Alert: Searches spiking for these stocks today - Yahoo Finance

May 10, 2025
pulisher
May 08, 2025

Galmed Pharmaceuticals Ltd’s Market Journey: Closing Weak at 1.29, Down -11.64 - DWinneX

May 08, 2025
pulisher
May 07, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by Analysts at StockNews.com - Defense World

May 07, 2025
pulisher
May 07, 2025

Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’ By Stocktwits - Investing.com India

May 07, 2025
pulisher
May 06, 2025

GLMD Advances Cancer Treatment with Promising Aramchol Results | GLMD Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

GLMD: Galmed's Aramchol Boosts Cancer Drug Efficacy in Early Studies | GLMD Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

Galmed Pharmaceuticals Unveils Promising Oncology Study Results with Aramchol - TipRanks

May 06, 2025
pulisher
May 06, 2025

Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models - PR Newswire

May 06, 2025
pulisher
May 03, 2025

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Up 41.3% in April - Defense World

May 03, 2025
pulisher
Apr 30, 2025

Galmed Pharmaceuticals Ltd (GLMD) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Sete News

Apr 30, 2025
pulisher
Apr 29, 2025

Understanding the Risks of Investing in Galmed Pharmaceuticals Ltd (GLMD) - knoxdaily.com

Apr 29, 2025
pulisher
Apr 29, 2025

Galmed Pharmaceuticals (NASDAQ:GLMD) Shares Cross Below 200 Day Moving Average – What’s Next? - Defense World

Apr 29, 2025
pulisher
Apr 29, 2025

StockNews.com Begins Coverage on Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World

Apr 29, 2025
pulisher
Apr 28, 2025

Galmed Pharmaceuticals (GLMD) Collaborates with VCU to Tackle GI Cancer Drug Resistance - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

GLMD’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com

Apr 28, 2025
pulisher
Apr 28, 2025

Understanding GLMD stock ratios for better investment decisions - uspostnews.com

Apr 28, 2025
pulisher
Apr 28, 2025

Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook - Benzinga

Apr 28, 2025
pulisher
Apr 28, 2025

Is Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) Stock Worth Investing In for High Returns? - Marketing Sentinel

Apr 28, 2025
pulisher
Apr 28, 2025

Galmed Signs Term Sheet to Develop New Semaglutide Formulation; Shares Up - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

Galmed (GLMD) Shares Climb Amid Strategic Drug Delivery Development - Stocks Telegraph

Apr 28, 2025
pulisher
Apr 28, 2025

Galmed Pharmaceuticals Signs Agreement for Novel Semaglutide Formulation - TipRanks

Apr 28, 2025
pulisher
Apr 28, 2025

Galmed (GLMD) Pharmaceuticals Signs Licensing Agreement for Drug - GuruFocus

Apr 28, 2025
pulisher
Apr 28, 2025

Galmed Signed Term Sheet For The Development Of Novel Semaglutide Sublingual Formulation - marketscreener.com

Apr 28, 2025
pulisher
Apr 28, 2025

Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation - PR Newswire

Apr 28, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 17, 2025

Galmed partners with VCU to target drug resistance - The Pharma Letter

Apr 17, 2025
pulisher
Apr 17, 2025

Galmed Pharmaceuticals Partners with VCU to Combat Drug Resistance in GI Cancers - TipRanks

Apr 17, 2025
pulisher
Apr 17, 2025

Galmed Pharmaceuticals Launches VCU Collaboration To Tackle Drug Resistance In Gi Cancers - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers - PR Newswire

Apr 17, 2025
pulisher
Apr 15, 2025

Galmed reports key biomarkers for heart and liver health By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Galmed Pharmaceuticals Unveils New Blood Markers for Aramchol - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

Galmed reports key biomarkers for heart and liver health - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor - Kilgore News Herald

Apr 15, 2025
pulisher
Apr 10, 2025

Galmed Pharmaceuticals Reports Positive Results from AM-001 Study of Aramchol Meglumine - TipRanks

Apr 10, 2025
pulisher
Apr 10, 2025

Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor - PR Newswire

Apr 10, 2025
pulisher
Apr 06, 2025

Maxim Group Reiterates “Hold” Rating for Galmed Pharmaceuticals (NASDAQ:GLMD) - Defense World

Apr 06, 2025

Galmed Pharmaceuticals Ltd (GLMD) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
자본화:     |  볼륨(24시간):